Hong Kong · Delayed Price · Currency is HKD Ascentage Pharma Group International Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 29% year-over-year to $44.5M, driven by product sales and expanding global trials. Cash runway extends through 2027, with multiple NDA filings expected next year. Key assets show strong differentiation and progress in both China and global markets.
-
Two novel products are commercialized in China, with multiple global Phase III trials underway for lead assets targeting hematologic malignancies. Recent clinical data show strong efficacy and safety, and U.S. commercialization is planned for 2028, with NDA filings expected next year.
Fiscal Year 2025
-
Revenue grew 90% year-over-year to $82.1M, driven by olverembatinib and lisaftoclax launches, with strong commercial expansion and a $353.2M year-end cash balance. Multiple global phase III trials are advancing, with NDA filings targeted for 2027.
-
Pivotal data for lisaftoclax in high-risk CLL/SLL and MDS/AML show strong efficacy and safety, with rapid dose ramp-up and no tumor lysis syndrome. POLARIS-1 and GLORIA-4 global phase III trials advance in ALL and MDS, while olverembatinib and novel pipeline assets expand therapeutic reach.
Fiscal Year 2024
-
2024 saw transformational growth with a 342% revenue increase, driven by Takeda's partnership and strong olverembatinib sales. Expanded NRDL coverage and a successful Nasdaq IPO further strengthened the outlook, with robust late-stage pipeline progress and global commercialization plans.